Colesevelam: In pediatric patients with heterozygous familial hypercholesterolemia

Pediatric Drugs

Volumn 12, Issue 2, 2010, Pages 133-140

  Perry, Caroline M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Profiles; HIV infections

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATORVASTATIN; BILE ACID; CEFALEXIN; COLESEVELAM; COLESTYRAMINE; DIGOXIN; ETHINYLESTRADIOL; FENOFIBRATE; GLIBENCLAMIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEVOTHYROXINE; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METOPROLOL; MEVINOLIN; NORETHISTERONE; PIOGLITAZONE; PLACEBO; PRAVASTATIN; QUINIDINE; REPAGLINIDE; SIMVASTATIN; TRIACYLGLYCEROL; VALPROIC ACID; VERAPAMIL; WARFARIN;

ABDOMINAL PAIN; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DECREASED APPETITE; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; EAR INFECTION; FAMILIAL HYPERCHOLESTEROLEMIA; FATIGUE; HUMAN; INFLUENZA; MONOTHERAPY; NAUSEA; PRIORITY JOURNAL; REVIEW; RHINITIS; RHINOPHARYNGITIS; UPPER RESPIRATORY TRACT INFECTION; VIRAL GASTROENTERITIS; VOMITING;

ALLYLAMINE; ANTICHOLESTEREMIC AGENTS; BILE ACIDS AND SALTS; CHILD; CHOLESTEROL, LDL; DRUG THERAPY, COMBINATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 77949460501     PISSN: 11745878     EISSN: 11792019     Source Type: Journal    
DOI: 10.2165/11204890-000000000-00000     Document Type: Review

References (23)

1. Civiera F, International Panel on Management of Familial Hypercholesterolemia. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis 2004; 173 (1): 55-68
2. Yuan G, Wang J, Hegele RA. Heterozygous familial hypercholesterolemia: an underrecognized cause of early cardiovascular disease. CanMed Assoc J 2006 Apr 11; 174 (8): 1124-1129
3. Stein EA, Marais AD, Szamosi T, et al. Colesevelam hydrochloride: efficacy and safety in pediatric subjects with heterozygous familial hypercholesterolemia. J Pediatr 2010 Feb; 156 (2): 231-236
4. Alexander W, Stein E. American Heart Association 2008 Scientific Sessions: familial hypercholesterolemia and colesevelam (Welchol). P&T 2009; 34 (1): 32
5. Kavey RE, Allada V, Daniels SR, et al. Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart AssociationExpertPanel on Population and Prevention Science; theCouncils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research - endorsed by the American Academy of Pediatrics. Circulation 2006; 114 (24): 2710-2738
6. Wierzbicki AS, Viljoen A. Hyperlipidaemia in paediatric patients: the role of lipid-lowering therapy in clinical practice. Drug Saf 2010; 33 (2): 115-125
7. Stein EA. Treatment of familial hypercholesterolemia with drugs in children. Arteriosclerosis 1989 Jan-Feb; 9 Suppl. 1: I145-51
8. Manghat P, Wierzbicki AS. Colesevelam: a specifically engineered bile acid sequestrant. Future Lipidol 2008; 3 (3): 237-255
9. Tonstad S, Ose L. Colestipol tablets in adolescents with familial hypercholesterolaemia. Acta Paediatr 1996 Sep; 85 (9): 1080-1082
10. Braunlin W, Zhorov E, Smisek D, et al. In vitro comparison of bile acid binding to colesevelam and other bile acid sequestrants. Polymer Preprints 2000; 41 (1): 708-709
11. Windler E, Zyriax B-C, Bamberger C, et al. Current strategies and recent advances in the therapy of hypercholesterolemia. Atheroscler Suppl 2009Dec 29; 10 (5): 1-4
12. Davidson MH, Dillon MA, Gordon B, et al. Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch Intern Med 1999 Sep 13; 159 (16): 1893-1900
13. Davidson MH. The use of colesevelam hydrochloride in the treatment of dyslipidemia: a review. Expert Opin Pharmacother 2007 Oct; 8 (15): 2569-2578
14. InsullWJr,Toth P,MullicanW, et al.Effectiveness of colesevelamhydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trial. Mayo Clin Proc 2001; 76 (10): 971-982
15. Hunninghake D, Insull W, Toth P, et al. Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively. Atherosclerosis 2001 Oct; 158 (2): 407-416
16. Bays HE, Davidson M, Jones MR, et al. Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia. Am J Cardiol 2006 Apr 15; 97 (8): 1198-1205
17. Daiichi Sankyo I. Welchol- (colesevelam hydrochloride) US prescribing information [online]. Available from URL: http://www.welchol.com/pdf/ Welchol-PI.pdf [Accessed 2010 Feb 4]
18. Melian EB, Plosker GL. Colesevelam.AmJ Cardiovasc Drug 2001; 1 (2): 141-146
19. Robinson DM, Keating GM. Colesevelam: a review of its use in hypercholesterolemia. Am J Cardiovasc Drugs 2007; 7 (6): 453-465
20. Bays H, Dujovne C. Colesevelam HCl: a non-systemic lipid-altering drug. Expert Opin Pharmacother 2003 May; 4 (5): 779-790
21. Brown KS, Armstrong IC, Wang A, et al. Effect of the bile acid sequestrant colesevelam on the pharmacokinetics of pioglitazone, repaglinide, estrogen estradiol, norethindrone, levothyroxine, and glyburide. J Clin Pharm. Epub 2009 Sep 29
22. Heller DP, Burke SK, Davidson DM, et al. Absorption of colesevelam hydrochloride in healthy volunteers. Ann Pharmacother 2002 Mar; 36: 398-403
23. Donovan JM, Kisicki JC, Stiles MR, et al. Effect of colesevelam on lovastatin pharmacokinetics. Ann Pharmacother 2002 Mar; 36: 392-397